创伤性脑损伤患者激动行为的药理干预:更新的系统审查
Tal Klimenko1, Marie-Michèle Briand1,2,3, Christophe Dumais1
1Faculty of Medicine, Université de Montréal, Montreal, Canada.
Journal of neurotrauma
|October 6, 2025
概括
目前的证据不足以推治疗创伤性脑损伤 (TBI) 后激动症的药物. 虽然德克斯梅德米丁在急性环境中表现有前途,但在所有TBI恢复阶段需要更多的研究.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 在创伤性脑损伤 (TBI) 后,兴奋的行为是常见的和具有挑战性的.
- 药理干预措施经常被使用,但它们的有效性和安全性需要持续评估.
研究的目的:
- 系统地审查和更新关于药理学药物的疗效和安全性的证据,以管理TBI后的激动行为.
- 综合来自随机对照试验,准实验和观察性研究的发现.
主要方法:
- 更新了2019年系统审查,并进行了全面的文献搜索,直至2025年1月.
- 包括32项研究 (21项原始研究+11项新研究) 对TBI相关激动症的9种药物类别进行了检查.
- 选了58项全文研究以供纳入.
主要成果:
- 在新的研究中,德克斯梅德托米丁在减少激动方面显示出潜在的益处.
- 与对照人群相比,新研究没有发现RISPERIDONE,OLANZAPINE,CARBAMAZEPINE或瓦尔酸具有显著的疗效.
- 普拉诺洛尔降低了激发强度,但没有降低激发频率;其他药物的益处仍然不清楚或不一致.
结论:
- 目前没有足够的数据来推针对TBI相关动荡的特定药物.
- 德克斯梅德托米丁在急性护理中可能有益;抗精神病药物,卡巴马西平和阿曼塔丁的益处尚不清楚.
- 进一步的研究在急性,康复和门诊环境中至关重要,以建立安全有效的药理疗法.
相关概念视频
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
655
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
655
01:26Psychosis: Goals of Pharmacotherapy
469
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
469
01:22Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822